These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 37772970)

  • 1. Immunotherapy in urothelial cancer: current status and future directions.
    Piombino C; Tonni E; Oltrecolli M; Pirola M; Pipitone S; Baldessari C; Dominici M; Sabbatini R; Vitale MG
    Expert Rev Anticancer Ther; 2023; 23(11):1141-1155. PubMed ID: 37772970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates for the treatment of urothelial carcinoma.
    Ravi P; McGregor BA
    Expert Opin Biol Ther; 2021 Jul; 21(7):915-922. PubMed ID: 32589063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
    Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on immunotherapy options for urothelial cancer.
    Bilgin B; Sendur MAN; Hizal M; Yalçın B
    Expert Opin Biol Ther; 2019 Dec; 19(12):1265-1274. PubMed ID: 31518156
    [No Abstract]   [Full Text] [Related]  

  • 8. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 12. Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy.
    You X; Zhu C; Yu P; Wang X; Wang Y; Wang J; Yu J; Wang K
    Biomed Pharmacother; 2024 Feb; 171():116152. PubMed ID: 38228034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime time for immunotherapy in advanced urothelial cancer.
    Jiang DM; Sridhar SS
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():24-32. PubMed ID: 30489031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Pharmacotherapy; 2017 Nov; 37(11):1391-1405. PubMed ID: 28950037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder cancer: shedding light on the most promising investigational drugs in clinical trials.
    Bin Riaz I; Khan AM; Catto JW; Hussain SA
    Expert Opin Investig Drugs; 2021 Aug; 30(8):837-855. PubMed ID: 34171206
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in the management of urothelial carcinoma: is immunotherapy the answer?
    Santopietro AL; Einstein D; Bellmunt J
    Expert Opin Pharmacother; 2021 Sep; 22(13):1743-1759. PubMed ID: 33905290
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
    Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
    BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.